CagriSema (cagrilintide-semaglutide) Phase 3a Trial Initiated for Type 2 Diabetes Management

Managing type 2 diabetes (T2D) often requires multifaceted approaches beyond diet and exercise, as current therapies may not achieve optimal glycemic control or weight management. GLP-1 receptor agonists like semaglutide are highly effective for both, but some patients still require further intervention. Amylin receptor agonists, such as cagrilintide, complement GLP-1 action by enhancing satiety and improving glycemic outcomes. The combination of these two mechanisms in CagriSema aims to provide synergistic benefits, addressing the unmet need for more potent and comprehensive metabolic control in T2D.

The REIMAGINE 1 study was a randomized, double-blind, parallel-group, phase 3a trial conducted across 42 sites in six countries. 189 adults with type 2 diabetes inadequately controlled by diet and exercise were randomized (2:1:2:1) to receive once-weekly subcutaneous cagrilintide 2.4 mg plus semaglutide 2.4 mg (CagriSema 2.4 mg), placebo, cagrilintide 1.0 mg plus semaglutide 1.0 mg (CagriSema 1.0 mg), or placebo for 40 weeks. The primary endpoint was change in HbA1c from baseline to week 40, with bodyweight change as a prespecified secondary endpoint. Safety was assessed in all participants receiving at least one dose.

Between March 19 and Dec 5, 2024, 294 individuals were screened, leading to the enrollment and randomization of 189 participants. These were assigned to CagriSema (2.4 mg each; n=62), CagriSema (1.0 mg each; n=63), or placebo (n=64). Participant demographics included 103 (54%) males and 86 (46%) females. The abstract provided enrollment and demographic data but did not report efficacy or safety outcomes regarding HbA1c or bodyweight changes at week 40. Efficacy and safety findings are anticipated following the completion of data analysis for this phase 3a trial.